Reference
- Lipton RB, Stewart WF. The epidemiology of migraine. Eur Neurol 1994;34(Suppl 2):6–11
- Dowson A, Jagger S. The UK Migraine Patient Survey: quality of life and treatment. Curr Med Res Opin 1999;15:241–53
- Peatfield RC. Migraine: which triptan? Hosp Med 1999;50:277–80
- Ferrari M. Migraine. Lancet 1998;351:1043–51
- Gawel MJ. A systematic review of the use of triptans in acute migraine. Can J Neurol Sci 2001;28(1): 31–41
- Goadsby PJ et al. Eletriptan in acute migraine: a double-blind, placebo-controlled comparison to sumatriptan. Neurology 2000;54:156–63
- Bomhof M et al. Comparisons of rizatriptan 10 mg vs. naratriptan 2.5 mg in migraine. Eur Neurol 1999;42:173–9
- Dodick DW. Oral almotriptan in the treatment of migraine: safety and tolerability. Headache 2001;41:449–55
- Belsey J. The clinical and financial impact of oral triptans in the management of migraine in the UK: a systematic review. J Med Econ 2000;3:35–47
- Department of Health, Statistics Division. Prescription Cost Analysis England 1998. London, 1999
- Olesen J. Analgesic headache. Br Med J 1995;310:479–80
- Saper JR. Ergotamine dependency: a review. Headache 1987;27:435–8
- NHS Executive. Clinical governance: quality in the new NHS. HSC 1999/065. London: Department of Health, 1999
- Royal College of General Practitioners. College viewpoint. Clinical governance: practical advice for primary care in England and Wales. Available from: the following URL: http://www.rcgp.org.uk/rcgp/corporate/position/advice/advice1.asp
- Spatz C. The chi square distribution. In: Basic Statistics: Tales of Distributions. Wadsworth, Belmont, 7th edn, pp. 278–97, 2001
- Edmeads J. The diagnosis and treatment of migraine: a clinician’s view. Eur. Neurol. 1994;34(Suppl 2):2–5
- Visser WH, de Vriend RHM, Jaspers NMWH, Ferrari MD. Sumatriptan in clinical practice: a two-year review of 453 migraine patients. Neurology 1996;47:46–51
- Silberstein SD. Drug-induced headache. Neurol. Clin. 1998;16:107–23